Organization
Escient Pharmaceuticals
5 clinical trials
Clinical trial
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria (CALM-CSU)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing CholangitisStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic PruritusStatus: Completed, Estimated PCD: 2021-07-08